Vaccine Preventable Disease and Vaccine Hesitancy

Peter J Hotez

doi:10.1016/j.mcna.2023.05.012

Vaccine Preventable Disease and Vaccine Hesitancy

Med Clin North Am. 2023 Nov;107(6):979-987. doi: 10.1016/j.mcna.2023.05.012. Epub 2023 Jul 11.

Author

Peter J Hotez¹

Affiliation

¹ Department of Pediatrics and Molecular Virology and Microbiology, Texas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Texas Medical Center, One Baylor Plaza, Suite 164a, Houston, TX 77030, USA. Electronic address: hotez@bcm.edu.

PMID: 37806729
DOI: 10.1016/j.mcna.2023.05.012

Abstract

Global immunization programs have saved tens of millions of lives over the last 2 decades. Now, the recent successes of COVID-19 vaccines having saved more than 3 million lives in North America during the pandemic may open the door to accelerate technologies for other emerging infection vaccines. New vaccines for respiratory syncytial virus, norovirus, influenza, herpes simplex virus, shingles, dengue fever, enteric bacterial infections, malaria, and Chagas disease are advancing through clinical development and could become ready for delivery over the next 5 years. The successful delivery of these new vaccines may require expanded advocacy and communications efforts.

Keywords: Antiscience; Antivaccine; Immunization; Vaccine; Vaccine acceptance; Vaccine hesitancy.

Publication types

Review

MeSH terms

COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Influenza Vaccines* / therapeutic use
Vaccination
Vaccination Hesitancy
Vaccine-Preventable Diseases* / epidemiology
Vaccine-Preventable Diseases* / prevention & control
Vaccines*

Substances

COVID-19 Vaccines
Vaccines
Influenza Vaccines